Cited 17 times in
Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김유선 | - |
dc.contributor.author | 허규하 | - |
dc.date.accessioned | 2016-02-04T10:52:42Z | - |
dc.date.available | 2016-02-04T10:52:42Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0041-1337 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/139178 | - |
dc.description.abstract | BACKGROUND: Everolimus and cyclosporine A (CsA) exhibit synergistic immunosuppressive activity when used in combination. We examined the safety and efficacy of the use of everolimus with a cyclosporine-sparing strategy in de novo renal transplant recipients. METHODS: A comparative, parallel, randomized, open-label 1-year study has been performed in 148 patients from five transplant centers to compare the efficacy and tolerability of everolimus and reduced exposure CsA (the investigational group) or enteric-coated mycophenolate sodium and standard-exposure CsA (the control group) in combination with basiliximab and steroids. The eligible subjects were randomly assigned at 1 month after transplantation. Efficacy failure (biopsy-proven acute rejection, death, graft loss, or loss to follow-up), safety, and renal function were evaluated. RESULTS: One graft loss has been reported in the control group and no patient death were reported in either group. The incidence of biopsy-proven acute rejection until 12 months after transplantation of the investigational group was 7.5%, compared to 11.1% of the control group (P=0.565). The mean estimated glomerular filtration rates of the investigational group at 12 months after transplantation was significantly higher (68.1 ± 16.8 ml/min/1.73 m(2)) than that of the control group (60.6 ± 15.8 ml/min/1.73 m(2); P=0.016). There was no significant difference (P>0.05) in the incidence of discontinuations and serious adverse events between the groups. CONCLUSION: The results of this study provide the evidences that (1) the calcineurin inhibitor (CNI) minimization by the introduction of everolimus after 1-month posttransplantation keeps the incidences of acute rejection and additional risks as low as the conventional immunosuppression; (2) it allows minimizing CNI exposure, consequently reducing CNI nephrotoxicity and preserving renal function. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 180~186 | - |
dc.relation.isPartOf | TRANSPLANTATION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Acute Disease | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antibodies, Monoclonal/administration & dosage | - |
dc.subject.MESH | Calcineurin Inhibitors/administration & dosage* | - |
dc.subject.MESH | Calcineurin Inhibitors/adverse effects | - |
dc.subject.MESH | Cyclosporine/administration & dosage* | - |
dc.subject.MESH | Cyclosporine/adverse effects | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Everolimus | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Graft Rejection/diagnosis | - |
dc.subject.MESH | Graft Rejection/immunology | - |
dc.subject.MESH | Graft Rejection/prevention & control* | - |
dc.subject.MESH | Graft Survival/drug effects* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents/administration & dosage* | - |
dc.subject.MESH | Immunosuppressive Agents/adverse effects | - |
dc.subject.MESH | Kidney Transplantation*/adverse effects | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mycophenolic Acid/administration & dosage | - |
dc.subject.MESH | Mycophenolic Acid/analogs & derivatives | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Recombinant Fusion Proteins/administration & dosage | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Sirolimus/administration & dosage | - |
dc.subject.MESH | Sirolimus/adverse effects | - |
dc.subject.MESH | Sirolimus/analogs & derivatives* | - |
dc.subject.MESH | Steroids/administration & dosage | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Oh, Chang-Kwon | - |
dc.contributor.googleauthor | Huh, Kyu Ha | - |
dc.contributor.googleauthor | Ha, Jongwon | - |
dc.contributor.googleauthor | Kim, Yeong Hoon | - |
dc.contributor.googleauthor | Kim, Yong-Lim | - |
dc.contributor.googleauthor | Kim, Yu Seun | - |
dc.identifier.doi | 10.1097/TP.0000000000000225 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00785 | - |
dc.contributor.localId | A04344 | - |
dc.relation.journalcode | J02754 | - |
dc.identifier.eissn | 1534-6080 | - |
dc.identifier.pmid | 24983307 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00007890-201501150-00032&LSLINK=80&D=ovft | - |
dc.subject.keyword | Kidney transplantation | - |
dc.subject.keyword | Everolimus | - |
dc.subject.keyword | Cyclosporine A | - |
dc.contributor.alternativeName | Kim, Yu Seun | - |
dc.contributor.alternativeName | Huh, Kyu Ha | - |
dc.contributor.affiliatedAuthor | Kim, Yu Seun | - |
dc.contributor.affiliatedAuthor | Huh, Kyu Ha | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 99 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 180 | - |
dc.citation.endPage | 186 | - |
dc.identifier.bibliographicCitation | TRANSPLANTATION, Vol.99(1) : 180-186, 2015 | - |
dc.identifier.rimsid | 43813 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.